CA3233822A1 - Flavonoid derivatives with gabaa receptor activity and methods of use - Google Patents
Flavonoid derivatives with gabaa receptor activity and methods of useInfo
- Publication number
- CA3233822A1 CA3233822A1 CA3233822A CA3233822A CA3233822A1 CA 3233822 A1 CA3233822 A1 CA 3233822A1 CA 3233822 A CA3233822 A CA 3233822A CA 3233822 A CA3233822 A CA 3233822A CA 3233822 A1 CA3233822 A1 CA 3233822A1
- Authority
- CA
- Canada
- Prior art keywords
- methods
- receptor activity
- flavonoid derivatives
- gabaa receptor
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253341P | 2021-10-07 | 2021-10-07 | |
| US63/253,341 | 2021-10-07 | ||
| PCT/US2022/045904 WO2023059802A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233822A1 true CA3233822A1 (en) | 2023-04-13 |
Family
ID=85803715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233822A Pending CA3233822A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240398821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538721A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118354770A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022361421A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233822A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023059802A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604831B2 (ja) * | 1975-10-20 | 1985-02-06 | 中外製薬株式会社 | 4(3h)−キナゾリノン誘導体の製法 |
| US5258478A (en) * | 1992-04-27 | 1993-11-02 | Florida State University | Low self-absorbing, intrinsically scintillating polymers |
| GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
| RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2808680A1 (en) * | 2010-08-24 | 2012-03-01 | The Regents Of The University Of California | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
| CN106478525A (zh) * | 2015-08-28 | 2017-03-08 | 南京理工大学 | 一种合成喹唑酮的方法 |
| CN109879820B (zh) * | 2019-02-26 | 2022-07-19 | 扬州大学 | 一种喹唑啉酮杂环化合物的合成方法 |
-
2022
- 2022-10-06 CN CN202280080629.4A patent/CN118354770A/zh active Pending
- 2022-10-06 JP JP2024521052A patent/JP2024538721A/ja active Pending
- 2022-10-06 AU AU2022361421A patent/AU2022361421A1/en active Pending
- 2022-10-06 CA CA3233822A patent/CA3233822A1/en active Pending
- 2022-10-06 WO PCT/US2022/045904 patent/WO2023059802A1/en not_active Ceased
- 2022-10-06 EP EP22879291.7A patent/EP4412605A4/en active Pending
- 2022-10-06 US US18/699,103 patent/US20240398821A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024538721A (ja) | 2024-10-23 |
| EP4412605A4 (en) | 2025-07-30 |
| CN118354770A (zh) | 2024-07-16 |
| US20240398821A1 (en) | 2024-12-05 |
| EP4412605A1 (en) | 2024-08-14 |
| AU2022361421A1 (en) | 2024-05-09 |
| WO2023059802A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12109429B2 (en) | Phototherapeutic light for treatment of pathogens | |
| Bellaver et al. | Guanosine inhibits LPS-induced pro-inflammatory response and oxidative stress in hippocampal astrocytes through the heme oxygenase-1 pathway | |
| EP4461355A3 (en) | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | |
| CL2012002381A1 (es) | Combinacion que comprende (2-hidroxietoxi)-amida del acido 6-(4-bromo-2- fluorofenilamino)-7-fluor-3-metil-3h-benzoimidazol-5-carboxilico o una sal del mismo y un agente anti-tumoral seleccionado de un grupo definido; uso para tratar un trastorno hiperproliferativo en un mamifero. | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| EA202091999A2 (ru) | Применение ингибиторов dpp iv | |
| GT200800105A (es) | Triazolopiridazinas como moduladores de tirosina cinasa | |
| CL2008002138A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridazin-4-il)imidazo[1,2-b]piridazina con actividad sobre la caseína quinasa 1 épsilon y/o 1 delta; procedimiento de preparación; composición farmacéutica; y uso para tratar trastornos del sueño, ritmo circadiano, alzheimer e hiperproliferanción de células. | |
| CU23423B7 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulación sanguínea | |
| BR0313562A (pt) | derivados de indol ou benzimidazol para a modulação da ikb-cinase | |
| AR037771A1 (es) | Moleculas pequenas para el tratamiento del crecimiento celular anormal | |
| NO20060871L (no) | Azepinderivater som farmasoytiske midler | |
| MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
| MX9303469A (es) | Derivados de benzimidazol, procedimiento para su preparacion, composicion farmaceutica que los contiene y procedimiento para preparar de la misma. | |
| UY28660A1 (es) | Antagonistas del factor de transcripcion c-maf de forma corta para el tratamiento del glaucoma | |
| CL2008002747A1 (es) | Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros. | |
| ITTO20060239A1 (it) | Formulazione per somministrazione orale con effetti salutistici sull'apparato cardiovascolare | |
| Micali et al. | Cimetidine therapy for epidermodysplasia verruciformis | |
| WO2019103658A3 (ru) | Производные 1,4-бензодиазепин-2-она и их применение | |
| MX374552B (es) | Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero. | |
| BR112021020141A2 (pt) | Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva | |
| UY30650A1 (es) | Sal de acido p-toluensulfonico de 5-amino-3-(2??-o-acetil-3??-desoxi-b-d-ribofuranosil)-3h-tiazol[4,5-d]pirimidin-2-ona y métodos de preparacion | |
| WO2017011356A3 (en) | Mcj inhibitors for use in treating drug-induced diseases and conditions | |
| MY133107A (en) | Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia | |
| MX2007004861A (es) | Derivados de sulfonamida novedosos como moduladores de receptor glucocorticoide para el tratamiento de enfermedades inflamatorias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240704 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240704 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241105 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250926 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250926 |